Non-Insulin Therapies for Diabetes Market Analysis and Forecast to 2027 by Recent Trends, Developments in Manufacturing Technology and Regional Growth Overview
Non-insulin treatments are most often used in people with type 2 diabetes, in whom the body does not make enough insulin or is unable to use the insulin it produces effectively. Medications without insulin work through a variety of mechanisms to lower blood glucose levels and keep them stable for optimal glycemic control. Sulfonylureas enhance insulin secretion by pancreatic cells, biguanides dramatically increase glucose metabolism by peripheral tissues while lowering hepatic glucose production, alpha glucosidase inhibitors delay digestion of sucrose in the intestine hail and some medications reduce postprandial sugar by blocking certain enzymes.
Get the PDF brochure here
The global market for non-insulin therapies for diabetes is expected to expand as the incidence rate and prevalence of diabetes increases. Treatments without insulin are most often used in type 2 diabetes, which accounts for about 90% of all diabetes cases worldwide. According to the 2017 Diabetes Atlas of the International Diabetes Federation (IDF), there were around 425 million people with diabetes worldwide, of which around 400 million have type II diabetes. According to a 2017 WHO study, diabetes is one of the top three causes of death from noncommunicable diseases in the world, with 114.4 million cases in China, 72.9 million cases in India and 30 , 2 million cases in the United States.
Diabetes has a significant economic impact around the world, which is expected to increase dramatically over the next few years. According to a March 2018 study by the American Diabetes Association, overall spending on diagnosed diabetes increased to US $ 327 billion in 2017, from US $ 245 billion in 2012. As a result, the global market for non-insulin therapies for diabetes is expected to develop in the years to come.
In addition, the companies are bringing innovative products and combination treatments to the market, which is driving the growth of the global non-insulin therapies for diabetes market. The Food and Drug Administration (FDA) cleared Novo Nordisk’s Ozempic (semiglutide), a once-weekly GLP-1 analogue that is believed to improve patient compliance, in 2017. The FDA cleared ertugliflozin ( Steglatro), a sodium-glucose 2 co-transporter (SGLT2 Inhibitor) jointly developed by Merck & Co. and Pfizer Inc., in December 2017, while the European Medicines Agency (EMA) cleared it in January 2018 .
The Global non-insulin therapies for diabetes market development is expected to be hampered by the high cost of new classes of drugs compared to traditional drugs, especially in places like Southeast Asia, where a significant number of people suffer from type 2 diabetes. GLP-1 cost around $ 492 for a 30-day treatment, while biguanides and sulfonylureas cost around $ 5-9 for a 30-day treatment.
Considering the largest diabetes spending in the United States, North America is expected to drive the growth of the global non-insulin therapy for diabetes market. According to the International Diabetes Federation (IDF), the United States recorded approximately 17,100 new cases of diabetes in 2017.
With the increasing prevalence of diabetes in China and India, which together have more than 180 million diabetic patients, Asia Pacific is one of the most profitable regions. According to the American Diabetes Association (ADA), between 2000 and 2035, the incidence of type 2 diabetes in South Asia is expected to increase by more than 150%.
The newer class of drugs, such as GLP-1 analogues or SGLT2, are increasingly being targeted by large companies. Since 2013, SGLT 2 inhibitors have been approved for use in the treatment of diabetes. The majority of SGL2 inhibitors, including Dapagliflozin, Canagliflozin, and Empagliflozin, were introduced after 2013. Although due to fierce competition in the industry, it can be difficult for a company to achieve higher large proportion of global non-insulin therapies for diabetes. Marlet.
Purchase this report with a flat rate US $ 2000 discount – https://www.coherentmarketinsights.com/promo/buynow/2042
Non-Insulin Therapies For Diabetes Market – Competitive Landscape
The major players operating in the global prosthetic sleeves market are as follows: AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis and Takeda Pharmaceuticals.
Key Highlights of the Non-Insulin Therapies For Diabetes Market Report Table of Contents
Chapter 1 Industry Overview
1.3 Scope of the research
1.4 Market Analysis by Regions
1.5 Global Non-Insulin Therapies for Diabetes Market Size Analysis from 2021 to 2027
11.6 COVID-19 outbreak: Non-insulin therapies impacting the diabetes industry
Chapter 2 Global Non-Insulin Therapies for Diabetes Competition by Types, Applications and Major Regions and Countries
2.1 Global Non-Insulin Therapies for Diabetes (Volume & Value) by Type
2.3 Global Non-Insulin Therapies for Diabetes (Volume & Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional production market analysis
Chapter 4 Global Non-Insulin Therapies for Diabetes Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Non-Insulin Therapies for Diabetes Market Analysis
Chapter 6 East Asia Non-Insulin Therapies For Diabetes Market Analysis
Chapter 7 Europe Diabetes Insulin-Free Therapies Market Analysis
Chapter 8 Southeast Asia Non-Insulin Therapies for Diabetes Market Analysis
Chapter 9 Southeast Asia Non-Insulin Therapies For Diabetes Market Analysis
Chapter 10 Middle East Non-Insulin Therapies for Diabetes Market Analysis
Chapter 11 Africa Non-Insulin Therapies for Diabetes Market Analysis
Chapter 12 Oceania Non-Insulin Therapies for Diabetes Market Analysis
Chapter 13 South America Non-Insulin Therapies for Diabetes Market Analysis
Chapter 14 Company Profiles and Key Figures of Non-Insulin Therapies for Diabetes
Chapter 15 Global Non-Insulin Therapies for Diabetes Market Forecast (2021-2027)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a leading market research and consulting firm providing action-ready syndicated research reports, personalized market analysis, advisory services and competitive analysis through various recommendations related to emerging market trends , technologies and potential opportunities in absolute dollars.
Consistent market information
1001 4th avenue, # 3200
Seattle, Washington 98154
Phone: United States +12067016702 / United Kingdom +4402081334027
Email: [email protected]